⏸️ Eli Lilly's COVID-19 Trial Paused

iPhone 12 event: 7 biggest announcements

Hey Global Investor, here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Tuesday Close) 3,511.93 −22.29 (0.63%)

NASDAQ (Tuesday Close) 11,863.90 −12.36 (0.10%)

FTSE 100 (5 PM IST) 5960.90 -8.81 (0.14%)

NIFTY 50 (Today’s Close) 11,971.05 +36.55 (0.31%)

USDINR (5 PM IST) 73.31 (1 Year +3.05%)

Eli Lilly COVID Antibody Trial Paused Because of Safety Concerns

Phase three trial of Lilly’s ACTIV-3 Monoclonal antibody treatment for COVID-19 paused due to potential safety concerns.

Background: Pharma companies have been aggressively working to bring treatments to COVID-19 to the market. Eli Lilly, Johnson & Johnson, and Gilead Sciences are some of the names working to address the pandemic.

What Happened? An independent data safety monitoring board (DSMB) recommended pausing enrollment in the US government-sponsored ACTIV-3 trial as per the company’s statement. Lilly didn’t advise the reason behind the panel’s recommendation. The news of the trial’s pause follows Johnson & Johnson’s similar decision because of a sick volunteer.

Eli Lilly is one of the several pharma companies developing monoclonal antibody therapies that can potentially stem the spread of early COVID-19 symptoms. Government health officials and pharmaceutical executives see the treatment as a potential cure.

The therapy has been in the spotlight in recent days after President Donald Trump received a similar treatment developed by Regeneron Pharmaceuticals. Post recovery, Trump has called the treatment as a “cure” and vowed to push for its approval in the US.

The ACTIV-3 trial is designed to test Lilly’s monoclonal antibody in combination with Gilead Science Inc.’s antiviral Remdesivir. Backed by the Trump administration, the 300-participant trial is part of the National Institute of Health’s “ACTIV” program to find a cure for COVID-19

Such pauses for large clinical trials are not uncommon and don’t necessarily mean anything is wrong with the treatment. The monitoring board must make a final decision before any further action. Lilly said it is supportive of the monitoring board’s decision to “cautiously ensure the safety of the patients participating in the study.”

Market reaction: Eli Lilly closed at $150.08, down 2.85%

Company Snapshot 📈

LLY $150.08 -4.41 (-2.85%)

Analyst Rating (15 Ratings) BUY 60% HOLD 40% SELL 0%

Newsworthy 📰

Wait a Minute: Johnson & Johnson’s coronavirus vaccine trial is paused after ‘adverse event’ in a participant (JNJ -2.29%)
No Freebies: Netflix stops offering free trials to U.S. viewers (NFLX +2.65%)
Hi, Speed: Apple’s iPhone 12 event: the 7 biggest announcements (AAPL -2.65%)

Later Today 🕒

6.00 PM IST: Initial jobless claims (regular state program, SA)
6.00 PM IST: Continuing jobless claims (regular state program, SA)
After Market Close: United Airlines Holdings Inc (UAL) Earnings
Before Market Open: Wells Fargo & Co (WFC) Earnings
Before Market Open: UnitedHealth Group Inc (UNH) Earnings
Before Market Open: Goldman Sachs Group Inc (GS) Earnings

“Fun Fact of The Day” 🌞

The word “emoji” comes from the Japanese words “e” and “moji”, which mean “picture” and “character”

Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities.

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.